Name:	espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones
Namespace Prefix:	espr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

Cash Payment To Be Received Upon Certain Commercial Milestones

No definition available.

Name:	espr_CashPaymentToBeReceivedUponCertainCommercialMilestones
Namespace Prefix:	espr_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

The amount of cash payment to the Company upon first commercial sales in the DSE Territory.

No definition available.

Name:	espr_CashPaymentToBeReceivedUponFirstCommercialSales
Namespace Prefix:	espr_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Potential one-time cash payments of up to $300 million upon the achievement of certain commercial milestones related to total net sales achievements in the DSE Territory.

No definition available.

Name:	espr_ContractWithCustomerLiabilityOneTimePaymentCurrent
Namespace Prefix:	espr_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

The amount of potential future payment which becomes due with the achievement of the primary MACE in the CLEAR Outcomes study and the CV risk reduction rate on the U.S. label, depending on the range of relative risk reduction in the CLEAR Outcomes study.

No definition available.

Name:	espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies
Namespace Prefix:	espr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

The amount of a potential future payment which becomes due with the first National Health Insurance price listing for NEXLETOL in the Otsuka Territory.

No definition available.

Name:	espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory
Namespace Prefix:	espr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

The amount of a potential future payment which becomes due with the submission of a Japanese New Drug Application (JNDA). in the Otsuka Territory.

No definition available.

Name:	espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory
Namespace Prefix:	espr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

The total amount of potential future payments related to total net sales achievements for Otsuka in Japan.

No definition available.

Name:	espr_FuturePaymentMilestoneSalesMilestones
Namespace Prefix:	espr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

Future Up-Front Payment

No definition available.

Name:	espr_FutureUpFrontPayment
Namespace Prefix:	espr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

The percentage of royalties to be received on net sales.

No definition available.

Name:	espr_PercentageOfRoyaltiesToBeReceivedOnNetSales
Namespace Prefix:	espr_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	duration

Proceeds From Milestone Payment

No definition available.

Name:	espr_ProceedsFromMilestonePayment
Namespace Prefix:	espr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

Royalty Rate On Net Sales

No definition available.

Name:	espr_RoyaltyRateOnNetSales
Namespace Prefix:	espr_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

Settlement Agreement Aggregate First Milestone Payment From Partner

No definition available.

Name:	espr_SettlementAgreementAggregateFirstMilestonePaymentFromPartner
Namespace Prefix:	espr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Settlement Agreement Aggregate Payment From Partner

No definition available.

Name:	espr_SettlementAgreementAggregatePaymentFromPartner
Namespace Prefix:	espr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Settlement Agreement Aggregate Second Milestone Payment From Partner

No definition available.

Name:	espr_SettlementAgreementAggregateSecondMilestonePaymentFromPartner
Namespace Prefix:	espr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Settlement Agreement, Time Required to Pay Cash Portion of Settlement

No definition available.

Name:	espr_SettlementAgreementTimeRequiredToPayCashPortionOfSettlement
Namespace Prefix:	espr_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

The amount of up-front payment received (paid) .

No definition available.

Name:	espr_UpFrontPayment
Namespace Prefix:	espr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Name:	srt_ProductOrServiceAxis=espr_RoyaltyRevenueFromDSEAndSaleOfBulkTabletsAndMilestonesReceivedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_ProductOrServiceAxis=espr_CollaborationRevenueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_CounterpartyNameAxis=espr_DaiichiSankyoEuropeGmbhMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_SubsidiarySaleOfStockAxis=espr_CommitmentOfferingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_CounterpartyNameAxis=espr_OtsukaPharmaceuticalCoLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_TypeOfArrangementAxis=espr_ExclusiveDevelopmentalActivitiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_CounterpartyNameAxis=espr_DaiichiSankyoCoLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: